Daily Respiratory Research Analysis
Three papers stood out today: an updated meta-analysis confirms that inhaled triple therapy (ICS/LABA/LAMA) meaningfully reduces severe exacerbations in moderate-to-severe asthma; a large genomic study identifies TP53 and BRCA2 germline pathogenic variants and a novel ALKBH2 variant associated with early-onset lung adenocarcinoma; and pooled clinical trial data show robust activity of datopotamab deruxtecan in heavily pretreated EGFR-mutated NSCLC.
Summary
Three papers stood out today: an updated meta-analysis confirms that inhaled triple therapy (ICS/LABA/LAMA) meaningfully reduces severe exacerbations in moderate-to-severe asthma; a large genomic study identifies TP53 and BRCA2 germline pathogenic variants and a novel ALKBH2 variant associated with early-onset lung adenocarcinoma; and pooled clinical trial data show robust activity of datopotamab deruxtecan in heavily pretreated EGFR-mutated NSCLC.
Research Themes
- Asthma step-up therapy and exacerbation prevention
- Germline genetics in early-onset lung adenocarcinoma
- Antibody–drug conjugates for EGFR-mutated NSCLC
Selected Articles
1. Triple therapy vs dual inhaler therapy for moderate-to-severe asthma: An updated systematic review and meta-analysis.
Across 26 RCTs (12,431 participants), triple therapy (ICS/LABA/LAMA) reduced severe exacerbations versus dual therapy in high-risk patients, with trivial changes in asthma control and quality of life and a small FEV1 gain, without increased serious adverse events. Effects were consistent across age, BMI, and exacerbation history, informing AAAAI/ACAAI guideline development.
Impact: This high-quality meta-analysis directly supports step-up therapy decisions in moderate-to-severe asthma and quantifies exacerbation reduction with high certainty. It is poised to influence guideline recommendations and clinical practice.
Clinical Implications: For patients at high risk of exacerbations who remain uncontrolled on ICS/LABA, stepping up to triple therapy should be considered, as it meaningfully reduces severe exacerbations without increasing serious adverse events. The small changes in ACQ/AQLQ and modest FEV1 gain suggest the primary benefit is exacerbation prevention.
Key Findings
- Triple therapy reduced severe exacerbations versus dual therapy in high-risk patients (RR 0.83, 95% CI 0.76–0.90; risk difference 5.3% fewer).
- Asthma control (ACQ-7) and quality of life (AQLQ) showed trivial improvements (MD -0.04 and 0.05, respectively).
- Pre-bronchodilator FEV1 improved modestly (MD 0.07 L) and serious adverse events did not increase.
- Effects were consistent across age, BMI, and exacerbation history; evidence certainty rated with GRADE.
Methodological Strengths
- Comprehensive search across multiple databases with paired independent screening and extraction.
- Random-effects meta-analyses with risk-of-bias assessment and GRADE certainty ratings; preregistered (OSF).
Limitations
- Heterogeneity across trials in drug formulations, devices, and dosing; varied trial durations.
- Patient-level modifiers (e.g., eosinophils, FeNO, smoking status) variably reported, limiting subgroup precision.
Future Directions: Head-to-head trials of specific triple combinations by biomarker strata (e.g., eosinophils/FeNO), longer-term safety, and implementation studies assessing exacerbation-driven step-up algorithms.
BACKGROUND: Long-acting muscarinic antagonists are typically added to inhaled corticosteroids (ICS) and long-acting β-agonists (LABA) for asthma management. OBJECTIVE: To systematically synthesize the benefits and harms of triple therapy (ICS/LABA/long-acting muscarinic antagonists) compared with dual therapy (ICS/LABA) for asthma management across key subpopulations as part of developing linked American Academy of Allergy, Asthma, and Immunology/American College of Allergy, Asthma, and Immunology guidelines. METHODS: We searched MEDLINE, EMBASE, the Cochrane Controlled Register of Trials, and the International Clinical Trials Registry Platform from January 1, 2020 to February 1, 2025, for randomized trials comparing inhaled triple therapy to dual therapy for asthma to update our previous systematic review. Paired reviewers independently screened citations, extracted data, and assessed the risk of bias. Random effects meta-analyses assessed asthma control (asthma control questionnaire-7; 0-6), asthma-related quality of life (asthma quality of life questionnaire; 1-7), prebronchodilator forced expiratory volume in 1 second, severe exacerbations, and serious adverse events. The Grading of Recommendations, Assessment, Development, and Evaluation approach informed the certainty of evidence. Open Science Framework Registration (https://osf.io/u8t4q/). RESULTS: A total of 26 trials randomized 12,431 participants. Compared with dual therapy, triple therapy reduces severe exacerbations in patients at high risk for future exacerbation (relative risk 0.83, 95% CI 0.76-0.90; risk difference 5.3% fewer;
2. Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma.
In Asians with early-onset LADC, germline TP53 (2.9%) and BRCA2 (1.7%) pathogenic variants were enriched versus later-onset cases, BRCA2 carriers showed homologous recombination deficiency, and a novel ALKBH2 frameshift variant (p.Glu35Alafs*54) was linked to risk with smoking-signature correlations. Findings support genetic predisposition and potential therapeutic vulnerabilities.
Impact: This large, integrated germline–somatic analysis identifies actionable hereditary risk in early-onset lung adenocarcinoma and a novel ALKBH2 variant, with implications for genetic testing, surveillance, and potential HRD-directed therapies.
Clinical Implications: Consider germline testing (TP53, BRCA2, and potentially ALKBH2) in early-onset LADC, particularly in never-smoking Asian women, to inform counseling and cascade testing. BRCA2-associated HRD suggests exploring platinum/PARP inhibitor sensitivity in trials.
Key Findings
- Germline TP53 and BRCA2 pathogenic variants were significantly more frequent in early-onset LADC (2.9% and 1.7%) than later-onset (0.14% and 0.21%).
- BRCA2 carriers exhibited homologous recombination deficiency via loss of the wild-type allele; BRCA1 GPV carriers had frequent concurrent TP53 somatic mutations.
- A novel germline ALKBH2 frameshift variant (p.Glu35Alafs*54) was associated with early-onset LADC risk and correlated with SBS4 smoking-related signatures and Brinkman index.
Methodological Strengths
- Large-scale multi-cohort design integrating WES/WGS with a case–control study (10,302 cases; 7,898 controls).
- Combined germline and somatic mutation analyses enabling mechanistic insights (e.g., HRD via LOH).
Limitations
- Predominantly Asian populations may limit generalizability beyond similar demographics.
- Observational design without interventional validation; ALKBH2 findings require external replication and functional studies.
Future Directions: External replication across ancestries, functional characterization of ALKBH2 variant, and trials testing HRD-directed therapies in BRCA2-mutated LADC.
INTRODUCTION: Up to 54% of all lung adenocarcinoma (LADC) cases in Asian populations occur in never-smoking women, suggesting that the impact of smoking and other environmental factors on the risk of early-onset LADC is minimal. Genetic factors may play a crucial role in disease development. METHODS: The prevalence of germline pathogenic variants (GPVs) of 454 hereditary cancer and DNA repair genes was evaluated by whole-exome and whole-genome sequencing of 348 early-onset LADC (aged ≤ 40 y) and 1425 later-onset LADC (aged ≥ 41 y) cases. A case-control study comprising 10,302 LADC cases and 7898 healthy controls was performed to identify moderate-risk genetic factors for the disease. Analysis of somatic mutations in 1278 patients with LADC, including 31 patients with GPVs, was also performed. RESULTS: The frequency of GPVs of TP53 and BRCA2 was significantly higher in those with early-onset LADC than in those with later-onset LADC. The detection rates for TP53 and BRCA2 GPVs were 2.9% and 1.7%, respectively, in patients with early-onset LADC, and 0.14% and 0.21%, respectively, in patients with later-onset LADC. Patients with BRCA1 GPVs exhibited a high incidence of concurrent TP53 somatic mutations. Patients with BRCA2 GPVs exhibited deficient homologous recombination in tumors by means of loss of the wild-type allele. A germline ALKBH2 variant, p.Glu35Alafs∗54, was associated with the risk of early-onset LADC, and patients with a deleterious variant exhibited a correlation between SBS4-related somatic mutations and the Brinkman index. CONCLUSION: TP53 and BRCA2 GPVs and the ALKBH2 novel variant are associated with early-onset LADC in Asians.
3. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
Pooling EGFR-mutated NSCLC patients from TROPION-Lung05 and -Lung01, Dato-DXd achieved a 43% confirmed response rate (4% complete), median DOR 7.0 months, PFS 5.8 months, and OS 15.6 months, with grade ≥3 TRAEs in 23% and SAEs in 6%. Activity was observed in a heavily pretreated, predominantly Asian cohort.
Impact: These results suggest a meaningful post-TKI option for EGFR-mutated NSCLC with manageable toxicity, supporting further randomized evaluation and potential incorporation into treatment algorithms.
Clinical Implications: Dato-DXd may be considered in clinical trial or compassionate settings for patients with EGFR-mutated NSCLC after EGFR TKI and platinum chemotherapy failure; monitoring for ADC-class toxicities remains essential.
Key Findings
- Confirmed objective response rate was 43% including 4% complete responses in 117 heavily pretreated EGFR-mutated NSCLC patients.
- Median duration of response was 7.0 months; median PFS 5.8 months and OS 15.6 months.
- Safety was consistent with prior studies with grade ≥3 treatment-related AEs at 23% and serious AEs at 6%; no new safety signals.
Methodological Strengths
- Pooled patient-level data from phase II and III studies focusing on a clinically relevant EGFR-mutant subgroup.
- Uniform Dato-DXd dosing (6 mg/kg) and detailed reporting of response and survival endpoints.
Limitations
- Exploratory pooled analysis without a randomized comparator within the EGFR-mutant subgroup limits causal inference.
- Predominantly Asian cohort (69%) may affect generalizability; follow-up details not fully specified.
Future Directions: Prospective randomized trials comparing Dato-DXd to docetaxel or other ADCs in EGFR-mutant post-TKI settings, and biomarker studies to refine patient selection.
BACKGROUND: This exploratory analysis assessed datopotamab deruxtecan (Dato-DXd) in pretreated patients with advanced or metastatic NSCLC and EGFR mutations. METHODS: Data were pooled from the phase II TROPION-Lung05 (NCT04484142) and phase III TROPION-Lung01 (NCT04656652) trials. Patients with EGFR-mutated advanced or metastatic NSCLC, who had received previous targeted therapies and platinum-based chemotherapy, received Dato-DXd 6 mg/kg (TROPION-Lung05) or were randomized to Dato-DXd 6 mg/kg or docetaxel 75 mg/m RESULTS: In total, 117 patients with EGFR mutations who received Dato-DXd were included in the pool. The population was heavily pretreated (median three lines of previous therapies; range, 1-5) and predominantly Asian (69%). The most common mutations were exon 19 deletion (51%), L858R (32%), and T790M (27%); more than one EGFR mutation could be present. The confirmed objective response rate was 43% (95% confidence interval [CI]: 34-52), including five complete responses (4%). Median duration of response was 7.0 months (95% CI: 4.2-9.8). Median progression-free survival and overall survival were 5.8 (95% CI: 5.4-8.2) and 15.6 months (95% CI: 13.1-19.0), respectively. The safety profile of Dato-DXd was consistent with the individual studies. No new safety signals were observed. Rates of grade greater than or equal to 3 treatment-related adverse events and serious adverse events were 23% and 6%, respectively. CONCLUSION: Dato-DXd demonstrated meaningful clinical activity in patients with EGFR-mutated advanced or metastatic NSCLC who had progressed on EGFR-directed therapies and chemotherapy, with an acceptable safety profile.